LicianPro

20/20 Biolabs, Inc. ·

AIDX 8-K 2026-11-16

20/20 Biolabs, Inc. (AIDX) 8-K dated 2026-11-16 — accession 0001213900-26-120734.

20/20 Biolabs, Inc. (AIDX) common stock.

20/20 Biolabs, Inc. filed a 8-K on 2026-11-16. Accession 0001213900-26-120734.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported AIDX revenue for 2025-12-31 was $2.0M. Net income was -$3.7M. Revenue was up 16.7% from 2024-12-31 to 2025-12-31.

Not investment advice. The AIDX SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr